Immunic is a clinical-stage biopharmaceutical company. Co. is pursuing three development programs. These include the vidofludimus calcium (IMU-838) program, which is focused on the development of oral formulations of a small molecule inhibitor of the enzyme dihydroorotate dehydrogenase; the IMU-935 program, which is focused on an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated, an immune cell-specific isoform of retinoic acid receptor-related orphan nuclear receptor gamma; and the IMU-856 program, which involves the development of a drug targeting the restoration of intestinal barrier function and regeneration of bowel epithelium. We show 21 historical shares outstanding datapoints in our IMUX shares outstanding history coverage, used to compute IMUX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing IMUX market cap history over the course of time is important for investors
interested in comparing IMUX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of IMUX versus a peer is one thing; comparing
IMUX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like IMUX can fluctuate over the course of history.
With this page we aim to empower investors researching IMUX by allowing them to research the IMUX market cap history. |
Free IMUX Email Alerts:
Video: The Importance of Market Cap
